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Our hypothesis is that in MOH there are metabolic
anomalies in brain areas which are implicated in drug
dependence and impulse control.
Objective
To identify changes in the dopamine D2 receptor in the
striatum and, evaluate neuropsychological and psycho-
pathological traits in MOH (before and after detoxifica-
tion), chronic migraine (CM) and episodic migraine (EM)
patients. Method: We studied 18 MOH, 14 CM, 18 EM
patients and 5 controls using Iodine-123-iodobenzamide
(IBZM) brain SPECT. MOH patients were studied before
and, one and six months after detoxification. Neuropsy-
chological and psychopathological traits were evaluated
using standard tests and auto-applied scales.
Results
SPECT quantification using spatially normalized images to
an IBZM template showed the following mean and stan-
dard deviations for striatal ratios: 1.77±0.15 (Controls),
1.73±0.25 (EM), 1.61±0.10 (MOH) and 1.53±0.10 (CM).
MOH and CM showed a similar downregulation of D2
receptors different to the D2 ratios seen in EM and con-
trols. Statistical differences were found between controls/
EM and CM (p<0.05). No differences were found in the
serial SPECT’s done to the MOH patients. Significant
differences were found between EM and MOH regarding
an anxiety disorder and in tests measuring attention,
executive function and verbal memory. There were also
differences between CM and MOH patients. MOH
patients’ quality of life and neuropsychology traits clearly
improved after 6 months, with a lower medication intake
(67.31 to 8.21pills/month).
Conclusion
There were two different groups regarding the IBZM-
SPECT results MOH/CM vs. EM/controls. MOH was
different than CM/EM neuropsychologically and psycho-
pathologically. MOH patients clinically improve after
detoxification even if their IBZM-SPECT does not. So,
maybe CM and MOH patients are clinically different
because of their cultural and personal pain-coping strate-
gies; and lower levels than expected of medication intake
or a longer history of headpain, could alter D2 receptors
of the brain.
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